Apixaban is a direct oral anticoagulant (DOAC) that works by selectively inhibiting Factor Xa, an essential component in the blood coagulation process. By doing so, it prevents the formation of harmful clots in veins and arteries.
Recommended for:
Patients with non-valvular atrial fibrillation at risk of stroke
Patients undergoing hip or knee replacement surgery
Individuals with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
Patients requiring long-term prevention of recurrent thromboembolic events
Apixaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment and prevention of deep vein thrombosis and pulmonary embolism, and for prophylaxis of venous thromboembolism after orthopedic surgery.
Apixaban tablets are taken orally, usually twice daily, with or without food. The exact dosage and duration depend on the indication and patient-specific risk factors and should be determined by a healthcare provider.
Contraindications:
Active pathological bleeding
Severe hepatic impairment with coagulopathy
Hypersensitivity to apixaban or any component of the formulation
Possible Side Effects:
Bleeding (nosebleeds, gastrointestinal bleeding, bruising)
Anaemia
Nausea
Allergic reactions (rash, itching, rare anaphylaxis)
